Dulan Lokuwithana is an Editor specializing in breaking news in the healthcare sector. With a focus on providing timely and accurate information, Dulan covers a wide range of topics including pharmaceutical developments, clinical trials, and market analysis. Dulan's articles aim to keep readers informed about the latest trends and news in the healthcare industry.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Dulan Lokuwithana's articles predominantly focus on the healthcare and pharmaceutical industry, with an emphasis on investment analysis and press releases. To effectively pitch to Dulan, provide insights into the financial implications of developments within biotechnology, drug development, or pharmaceutical companies. This could include potential market impacts of new product launches, M&A activities, regulatory approvals or clinical trial results.
Given the high percentage of coverage attributes related to investment analysis and private sector announcements in his work, Dulan may be interested in pitches from professionals who can offer financial perspectives on company developments or those who have access to exclusive data supporting market trends within the healthcare and pharmaceutical sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Rockwell Medical (RMTI) stock could double by 2027 despite recent selloff, says Seeking Alpha analyst. Read more here.
McKesson (MCK) and Cencora (COR) ordered by a jury in Baltimore to pay $266M in damages to the city for their role in causing opioid crisis. Read morre here.
Cannabis-related ETFs gains as Trump nominates pro-marijuana reform Congressman Matt Gaetz as next U.S. attorney general. Read more here.
Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate called LM-299 from LaNova. Read more here.
Biden administration plans to adjust Medicare Star Ratings System, so as to lower the impact of call center scores amid lawsuits by managed care firms. Read more here.
PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read more here.
Grifols (GRFS) stock gains as banks aim to finalize an €11B debt package for Brookfield's (BAM) plan to take the healthcare company private. Read more here.
Biogen (BIIB) stock rises as EU drug regulator endorses Leqembi for early Alzheimer's treatment, paving the way for marketing authorization decision. Read more here.
Nuvectis Pharma (NVCT) stock falls as company posts interim data from a Phase 1b trial for its ovarian cancer drug candidate. Read ,more here.
PROCEPT BioRobotics (PRCT) stock slips as Jefferies launches its coverage with Hold rating, citing concerns over valuation.Read more here.
(833) 317-6278 
